Welcome!

News Feed Item

Acquisitions, Appointments, Patent Grant, Technical Updates, and Awareness Campaign - Research Reports on Covidien, Biogen Idec, Achillion, Intercept and Mylan

Editor Note: For more information about this release, please scroll to bottom.

NEW YORK, August 28, 2014 /PRNewswire/ --

Today, Analysts Review released its research reports regarding Covidien plc (NYSE: COV), Biogen Idec Inc. (NASDAQ: BIIB), Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN), Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) and Mylan Inc. (NASDAQ: MYL). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6032-100free.

Covidien plc Research Reports
On August 22, 2014, Covidien plc (Covidien) announced that it has acquired Reverse Medical Corporation, a medical device company dedicated to the management of vascular disease. Covidien stated that the business of Reverse Medical Corporation will be reported as a part of the Company's Neurovascular product line in the Medical Devices segment. "Covidien is focused on technologies that deliver improved patient care through clinically relevant and economically valuable solutions," said Brett Wall, President, Neurovascular, Covidien. "The acquisition of Reverse Medical is complementary to our existing portfolio and will allow us to leverage existing vascular technologies to compete in the worldwide vascular embolization market, which is growing at a double digit rate." The full research reports on Covidien are available to download free of charge at:

http://www.analystsreview.com/Aug-28-2014/COV/report.pdf

Biogen Idec Inc. Research Reports
On August 21, 2014, Biogen Idec Inc. (Biogen Idec) announced that Adriana (Andi) Karaboutis has been appointed as Executive Vice President, Technology and Business Solutions, effective September 24, 2014. Biogen Idec stated that in her new role, Ms. Karaboutis will report to George Scangos, Ph.D, CEO and will lead information technology operations and advance the Company's use of technology and data to enhance overall engagement with patients and healthcare providers. Biogen Idec informed that prior to her new role, Ms. Karaboutis has worked with Dell as Vice President and Chief Information Officer. "Andi is a remarkable technology leader who will enable Biogen Idec to infuse digital innovation at all levels of our business and research organizations," said Dr. Scangos. The full research reports on Biogen Idec are available to download free of charge at:

http://www.analystsreview.com/Aug-28-2014/BIIB/report.pdf

Achillion Pharmaceuticals, Inc. Research Reports
On August 19, 2014, Achillion Pharmaceuticals, Inc. (Achillion) announced that the U.S. Patent & Trademark Office has granted the Company U.S. Patent No. 8,809,313, covering composition-of-matter and method of use claims for ACH-3102 and structurally related NS5A inhibitor compounds. According to the Company, ACH-3102 is its second generation Phase 2 NS5A inhibitor being examined for the cure of chronic hepatitis C virus (HCV) infection. Achillion informed that this patent is entitled "Substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes useful for treating HCV infections," and provides a patent term which lasts until 2032. Milind Deshpande, President and CEO, Achillion said, "With the issuance of this patent for our differentiated NS5A inhibitor, ACH-3102, along with the previously granted patent for sovaprevir, our NS3/4A protease inhibitor, we are pleased to recognize the talented Achillion team that discovered and has advanced these compounds into Phase 2 trials evaluating their use in all-oral combination regimens for the treatment of chronic HCV." The full research reports on Achillion are available to download free of charge at:

http://www.analystsreview.com/Aug-28-2014/ACHN/report.pdf

Intercept Pharmaceuticals, Inc. Research Reports
On August 25, 2014, shares in Intercept Pharmaceuticals, Inc. (Intercept) moved up 2.59% to end the day at $294.56, outperforming the S&P 500 Index which gained 0.48% over the same day. During the day, the stock opened at $294.25 and fluctuated within the range of $291.52 and $299.68. As of August 25, 2014, the Company had a market capitalization of $6.09 billion. The full research reports on Intercept are available to download free of charge at:

http://www.analystsreview.com/Aug-28-2014/ICPT/report.pdf

Mylan Inc. Research Reports
On August 25, 2014, Mylan Specialty, the specialty pharmaceutical business of Mylan Inc. (Mylan), along with Adrian Peterson, Pro Football Player and EpiPen (epinephrine) Auto-Injector Spokesperson Adrian Peterson, announced the three winners of Ready2Go MVP Draft. Mylan stated that the winners also shot an educational video with Peterson, aimed at assisting people identify the signs and symptoms of anaphylaxis and how to respond if it occurs. According to the Company, Ready2Go MVP Draft is a countrywide search to discover kids who have potentially life-threatening allergies and are geared up to respond to the occurrence of life-threatening allergic reaction (anaphylaxis). Mylan informed that Being Ready2Go implies avoiding ones allergic triggers, knowing the signs and symptoms of anaphylaxis, having access to two EpiPen Auto-Injectors and seeking medical help in case of anaphylaxis. Mylan stated that the winners in the 3 categories were: Evan Johnson, in age group 5-9 years from FriscoTexas, Nathaniel Campen in age group 10-13 yrs from Rosemount, Minnesota and Katherine Schug in age group 14-18 years from Scotch Plains, New Jersey. The full research reports on Mylan are available to download free of charge at:

http://www.analystsreview.com/Aug-28-2014/MYL/report.pdf

About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.

EDITOR'S NOTES:

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


SOURCE Analysts Review

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
When shopping for a new data processing platform for IoT solutions, many development teams want to be able to test-drive options before making a choice. Yet when evaluating an IoT solution, it’s simply not feasible to do so at scale with physical devices. Building a sensor simulator is the next best choice; however, generating a realistic simulation at very high TPS with ease of configurability is a formidable challenge. When dealing with multiple application or transport protocols, you would be...
As businesses adopt functionalities in cloud computing, it’s imperative that IT operations consistently ensure cloud systems work correctly – all of the time, and to their best capabilities. In his session at @BigDataExpo, Bernd Harzog, CEO and founder of OpsDataStore, presented an industry answer to the common question, “Are you running IT operations as efficiently and as cost effectively as you need to?” He then expounded on the industry issues he frequently came up against as an analyst, and ...
SYS-CON Events announced today that App2Cloud will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct. 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. App2Cloud is an online Platform, specializing in migrating legacy applications to any Cloud Providers (AWS, Azure, Google Cloud).
In his session at @DevOpsSummit at 20th Cloud Expo, Kelly Looney, director of DevOps consulting for Skytap, showed how an incremental approach to introducing containers into complex, distributed applications results in modernization with less risk and more reward. He also shared the story of how Skytap used Docker to get out of the business of managing infrastructure, and into the business of delivering innovation and business value. Attendees learned how up-front planning allows for a clean sep...
Blockchain is a shared, secure record of exchange that establishes trust, accountability and transparency across supply chain networks. Supported by the Linux Foundation's open source, open-standards based Hyperledger Project, Blockchain has the potential to improve regulatory compliance, reduce cost and time for product recall as well as advance trade. Are you curious about Blockchain and how it can provide you with new opportunities for innovation and growth? In her session at 20th Cloud Exp...
IoT is at the core or many Digital Transformation initiatives with the goal of re-inventing a company's business model. We all agree that collecting relevant IoT data will result in massive amounts of data needing to be stored. However, with the rapid development of IoT devices and ongoing business model transformation, we are not able to predict the volume and growth of IoT data. And with the lack of IoT history, traditional methods of IT and infrastructure planning based on the past do not app...
To get the most out of their data, successful companies are not focusing on queries and data lakes, they are actively integrating analytics into their operations with a data-first application development approach. Real-time adjustments to improve revenues, reduce costs, or mitigate risk rely on applications that minimize latency on a variety of data sources. Jack Norris reviews best practices to show how companies develop, deploy, and dynamically update these applications and how this data-first...
Intelligent Automation is now one of the key business imperatives for CIOs and CISOs impacting all areas of business today. In his session at 21st Cloud Expo, Brian Boeggeman, VP Alliances & Partnerships at Ayehu, will talk about how business value is created and delivered through intelligent automation to today’s enterprises. The open ecosystem platform approach toward Intelligent Automation that Ayehu delivers to the market is core to enabling the creation of the self-driving enterprise.
"At the keynote this morning we spoke about the value proposition of Nutanix, of having a DevOps culture and a mindset, and the business outcomes of achieving agility and scale, which everybody here is trying to accomplish," noted Mark Lavi, DevOps Solution Architect at Nutanix, in this SYS-CON.tv interview at @DevOpsSummit at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
Internet-of-Things discussions can end up either going down the consumer gadget rabbit hole or focused on the sort of data logging that industrial manufacturers have been doing forever. However, in fact, companies today are already using IoT data both to optimize their operational technology and to improve the experience of customer interactions in novel ways. In his session at @ThingsExpo, Gordon Haff, Red Hat Technology Evangelist, shared examples from a wide range of industries – including en...
In IT, we sometimes coin terms for things before we know exactly what they are and how they’ll be used. The resulting terms may capture a common set of aspirations and goals – as “cloud” did broadly for on-demand, self-service, and flexible computing. But such a term can also lump together diverse and even competing practices, technologies, and priorities to the point where important distinctions are glossed over and lost.
"We're here to tell the world about our cloud-scale infrastructure that we have at Juniper combined with the world-class security that we put into the cloud," explained Lisa Guess, VP of Systems Engineering at Juniper Networks, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
Enterprise architects are increasingly adopting multi-cloud strategies as they seek to utilize existing data center assets, leverage the advantages of cloud computing and avoid cloud vendor lock-in. This requires a globally aware traffic management strategy that can monitor infrastructure health across data centers and end-user experience globally, while responding to control changes and system specification at the speed of today’s DevOps teams. In his session at 20th Cloud Expo, Josh Gray, Chie...
Consumers increasingly expect their electronic "things" to be connected to smart phones, tablets and the Internet. When that thing happens to be a medical device, the risks and benefits of connectivity must be carefully weighed. Once the decision is made that connecting the device is beneficial, medical device manufacturers must design their products to maintain patient safety and prevent compromised personal health information in the face of cybersecurity threats. In his session at @ThingsExpo...
All organizations that did not originate this moment have a pre-existing culture as well as legacy technology and processes that can be more or less amenable to DevOps implementation. That organizational culture is influenced by the personalities and management styles of Executive Management, the wider culture in which the organization is situated, and the personalities of key team members at all levels of the organization. This culture and entrenched interests usually throw a wrench in the work...